Atrial Fibrillation Surgery Market by Product, Indication, End-User

Description

List of Tables

[182 Pages Report] The Atrial Fibrillation Surgery Market size was estimated at USD 2.67 billion in 2023 and expected to reach USD 2.90 billion in 2024, at a CAGR 9.00% to reach USD 4.88 billion by 2030.

Atrial fibrillation surgery is a medical procedure to treat atrial fibrillation (AFib), an irregular and often rapid heart rate that can lead to poor blood flow, stroke, and other cardiovascular complications. Major types of atrial fibrillation surgeries include catheter ablation, surgical ablation, and left atrial appendage closure (LAAC). Over the years, there has been a significant prevalence of chronic diseases such as diabetes and hypertension, which are key risk factors for developing AFib; as a result, demand for effective AFib treatment options has surged. Innovations in minimally invasive techniques, such as catheter ablation, have significantly improved patient outcomes while reducing recovery time. However, product recalls associated with AFib surgical products, limited reimbursements for surgeries, and limited availability of surgeons to conduct the procedure also impact the market. Market players are creating affordable devices or techniques that enable greater accessibility to life-saving treatments for patients across different socioeconomic backgrounds. Continued research in areas such as artificial intelligence, robotics, and bioelectronic medicine is expected to lead to the development of innovative AFib surgery solutions that further improve patient outcomes and minimize complications.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.67 billion
Estimated Year [2024]	USD 2.90 billion
Forecast Year [2030]	USD 4.88 billion
CAGR (%)	9.00%

Product: Minimally invasive procedures are on demand with the rising utilization of catheter-based procedures

Catheter ablation products are minimally invasive procedures used to treat atrial fibrillation (AF) by isolating the pulmonary veins and creating lesions in the heart tissue to disrupt the abnormal electrical signals. These products offer a less invasive option for patients who are not suitable candidates for open-heart surgery or those who prefer a shorter recovery time. Surgical ablation products encompass various techniques such as maze procedure (cut-and-sew technique), radiofrequency (RF) ablation, and cryoablation performed during open-heart surgery or using minimally invasive approaches, including thoracoscopic surgery. These products address more complex cardiac arrhythmias that cannot be effectively treated alone with catheter-based techniques. While catheter-based procedures are favored due to their minimally invasive nature and quicker recovery times, surgical options offer a more comprehensive treatment for complex arrhythmias that cannot be adequately addressed using catheter techniques alone.

Indication: Emergence of maze procedure as a preferred treatment for atrial fibrillation

Arrhythmias are irregular heart rhythms induced by abnormal electrical activity in the heart. Atrial fibrillation is the most common type of arrhythmia affecting millions of people worldwide. The maze procedure, pulmonary vein isolation (PVI), and left atrial appendage closure (LAAC) are common surgical options for AFib treatment. Atrial flutter is a less common arrhythmia characterized by rapid and regular electrical signals originating from the atria. Catheter ablation is the preferred treatment option; however, atrial fibrillation surgery may be necessary in cases where ablation is unsuccessful or not suitable due to patient factors. Supraventricular tachycardia refers to rapid heart rhythms originating above the ventricles. Catheter ablation is the primary treatment for SVT, and atrial fibrillation surgery may be considered in cases with multiple arrhythmogenic foci or when ablation fails.

End-User: Accelerating cases of atrial fibrillation surgeries conducted in cardiology and multi-specialty centers

In the atrial fibrillation surgery landscape, cardiology and multi-specialty practices have distinct requirements and preferences regarding surgical interventions for atrial fibrillation. Cardiology-focused practices prioritize specialized devices explicitly designed for atrial fibrillation treatment, while multi-specialty settings seek versatility across disciplines and patient populations. Cardiologists specialized in diagnosing and treating heart diseases, including atrial fibrillation, necessitating advanced devices and procedures and new irrigated radiofrequency ablation catheters. Minimally invasive methods such as catheter ablation are the preferred choice for cardiologists due to their high success rates, reduced patient discomfort, and shorter recovery times. Multi-specialty practices provide an integrated approach to patient care by encompassing various medical disciplines under one roof. In these settings, diagnostic equipment and tools comprise ECG machines, echocardiography systems, and cardiac monitoring devices for accurate diagnosis and management of atrial fibrillation.

Regional Insights

North America's atrial fibrillation surgery market observes an advancing landscape driven by the well-established healthcare infrastructure and favorable reimbursement policies to conduct surgical procedures. There have been several innovative medication products and devices approved by the U.S. Food & Drug Administration (FDA) and Health Canada in the region, portraying an improved development scenario. In Asia-Pacific, countries such as India, Japan, and China have seen a rapid increase in AFib surgeries due to a large patient pool suffering from cardiovascular diseases uptaking surgical procedures. Substantial growth in medical tourism in Asia has accelerated the number of surgeries conducted in the region, expanding the need for advanced surgical tools and devices. The production aspect of AF surgery is growing in Asia, especially in China and Japan, due to the presence of major medical device manufacturers focusing on developing cost-effective solutions to cater to the ever-growing demand for affordable healthcare services. Europe is another significant market for AFib, with many European-based companies focusing on developing innovative cardiac devices used during AF surgeries. Key players have made substantial investments in research and development activities aimed at advancing surgical technologies for treating atrial fibrillation patients effectively.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Atrial Fibrillation Surgery Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atrial Fibrillation Surgery Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Atrial Fibrillation Surgery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acesion Pharma ApS, Acutus Medical, Inc, Affera, Inc., AFreeze GmbH, Atrian Medical Ltd., AtriCure, Inc., AuriGen Medical, BIOTRONIK SE & CO. KG, Boston Scientific Corporation, Cardiofocus, Inc., CathRx Ltd, Cook Group Incorporated, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc., Healium Medical, Japan Lifeline Co., Johnson & Johnson Services, Inc., Kardium Inc., Koninklijke Philips N.V., Medtronic PLC, OMEICOS Therapeutics GmbH, Osypka AG, SentiAR, Inc, Siemens Healthcare GmbH, Stryker Corporation, Terumo Corporation, Thryv Therapeutics Inc., Toray Medical Co., Ltd., Vanguard AG, and Volta Medical.

Market Segmentation & Coverage

This research report categorizes the Atrial Fibrillation Surgery Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Cardiac Cryoablation Catheters
- Cardiac Mapping System

Indication
- Atrial Fibrillation (AFib)
- Atrial Flutter
- Supraventricular Tachycardia (SVT)

End-User
- Cardiology
- Multi Specialities

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Atrial Fibrillation Surgery Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atrial Fibrillation Surgery Market?

3. What are the technology trends and regulatory frameworks in the Atrial Fibrillation Surgery Market?

4. What is the market share of the leading vendors in the Atrial Fibrillation Surgery Market?

5. Which modes and strategic moves are suitable for entering the Atrial Fibrillation Surgery Market?

Product Code: MRR-436901065DB6

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rise in prevalence of atrial fibrillation in geriatric population
  - 5.1.1.2. Development in preference of catheter ablation for cardiac arrhythmia treatment
  - 5.1.1.3. Growing number of AF programs to enhance public awareness
- 5.1.2. Restraints
  - 5.1.2.1. Regulatory issues associated with the devices
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing need for minimally invasive procedures, smaller cardiac incisions, and faster post-surgical recovery times
  - 5.1.3.2. Technological advances for catheter ablation of atrial fibrillation
- 5.1.4. Challenges
  - 5.1.4.1. Lack of skilled professionals and awareness among the people about the surgery
5.2. Market Segmentation Analysis
- 5.2.1. Product: Minimally invasive procedures are on demand with the rising utilization of catheter-based procedures
- 5.2.2. Indication: Emergence of maze procedure as a preferred treatment for atrial fibrillation
- 5.2.3. End-User: Accelerating cases of atrial fibrillation surgeries conducted in cardiology and multi-specialty centers
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Atrial Fibrillation Surgery Market, by Product

6.1. Introduction
6.2. Cardiac Cryoablation Catheters
6.3. Cardiac Mapping System

7. Atrial Fibrillation Surgery Market, by Indication

7.1. Introduction
7.2. Atrial Fibrillation (AFib)
7.3. Atrial Flutter
7.4. Supraventricular Tachycardia (SVT)

8. Atrial Fibrillation Surgery Market, by End-User

8.1. Introduction
8.2. Cardiology
8.3. Multi Specialities

9. Americas Atrial Fibrillation Surgery Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Atrial Fibrillation Surgery Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Atrial Fibrillation Surgery Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. GE HealthCare Launches CardioVisio for Atrial Fibrillation, a Digital, Patient-Centric Clinical Decision Support Tool to Enable Precision Care
- 12.3.2. Biosense Webster Receives FDA Approval for Multiple Atrial Fibrillation Ablation Products to be Used in a Workflow Without Fluoroscopy
- 12.3.3. Medtronic Receives CE Mark Approval For Affera Mapping And Ablation System To Treat Atrial Arrhythmias
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio